Quick Answer
Semnur Pharmaceuticals, Inc. reported Net Income of -$160.42 million for fiscal year 2025.
Semnur Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$160.42M | -3320.4% |
| 2024 | -$4.69M | -841.5% |
| 2023 | $632.5K | +250.8% |
| 2022 | -$419.4K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$152.59M | -11656.1% | -15174.7% |
| June 30, 2025 | -$999.0K | +10.0% | -50.2% |
| March 31, 2025 | -$665.0K | +55.8% | +48.8% |
| September 30, 2024 | -$1.30M | -305.8% | -16.9% |
| June 30, 2024 | -$1.11M | -342.5% | +26.3% |
| March 31, 2024 | -$1.51M | -49.2% | -338.8% |
| September 30, 2023 | $630.6K | +105.1% | +37.8% |
| June 30, 2023 | $457.7K | +1583.8% | +145.4% |
- Semnur Pharmaceuticals, Inc. showed a decrease of -3320.4% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Semnur Pharmaceuticals, Inc.’s net income has declined by 38149.8% (from -$419.4 thousand to -$160.42 million).
- The most recent figure is from Semnur Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: